{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:07:35Z","timestamp":1790006855677,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04107-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:14:11Z","timestamp":1782252851000},"page":"2887-2910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-vitro Assessment of Immediate Release Rivaroxaban Coated Fixed Dose Combination Tablets with Extended Release Molnupiravir for the Management of Coagulopathy Associated with COVID"],"prefix":"10.1007","volume":"43","author":[{"given":"Abu","family":"Mohiuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koustav","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-2925","authenticated-orcid":false,"given":"Santanu","family":"Kaity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"4107_CR1","doi-asserted-by":"publisher","first-page":"19321","DOI":"10.1038\/s41598-025-99786-z","volume":"15","author":"H Ishikura","year":"2025","unstructured":"Ishikura H, Irie Y, Nakashio M, et al. Management of COVID-19-associated coagulopathy in critically ill patients and the risk of acquired von Willebrand syndrome. Sci Rep. 2025;15:19321. https:\/\/doi.org\/10.1038\/s41598-025-99786-z.","journal-title":"Sci Rep"},{"key":"4107_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41577-022-00762-9","volume":"22","author":"EM Conway","year":"2022","unstructured":"Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22:639\u201349. https:\/\/doi.org\/10.1038\/s41577-022-00762-9.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4107_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.amjms.2021.10.012","volume":"363","author":"J Pl\u00e1\u0161ek","year":"2022","unstructured":"Pl\u00e1\u0161ek J, Gumulec J, M\u00e1ca J, \u0160karda J, Proch\u00e1zka V, Gr\u00e9zl T, V\u00e1clav\u00edk J. COVID-19 associated coagulopathy: mechanisms and host-directed treatment. Am J Med Sci. 2022 Jun;363(6):465\u201375. https:\/\/doi.org\/10.1016\/j.amjms.2021.10.012.","journal-title":"Am J Med Sci."},{"key":"4107_CR4","doi-asserted-by":"crossref","unstructured":"Saima May Sidik. Heart disease after Covid: what the data say. 2022.","DOI":"10.1038\/d41586-022-02074-3"},{"issue":"5","key":"4107_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41569-021-00631-3","volume":"19","author":"BA Satterfield","year":"2022","unstructured":"Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol. 2022;19(5):332\u201341.","journal-title":"Nat Rev Cardiol."},{"issue":"5","key":"4107_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jece.2024.113665","volume":"12","author":"A Demir","year":"2024","unstructured":"Demir A, Oturan N, \u00d6zyurt B, Trellu C, Oturan MA. Degradation of antiviral drug molnupiravir using a dual-function FeIIFeIIILDH@ carbon felt cathode in the heterogeneous electro-Fenton process: Kinetics and mineralization study. J Environ Chem Eng. 2024;12(5):113665.","journal-title":"J Environ Chem Eng"},{"key":"4107_CR7","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additionaloral-antiviral-treatment-covid-19-certain. Accessed 05\/10\/2025."},{"issue":"2","key":"4107_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13732","volume":"17","author":"BM Maas","year":"2024","unstructured":"Maas BM, Strizki J, Miller RR, Kumar S, Brown M, Johnson MG, Cheng M, De Anda C, Rizk ML, Stone JA. Molnupiravir: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(2):e13732. https:\/\/doi.org\/10.1111\/cts.13732.","journal-title":"Clin Transl Sci."},{"issue":"4","key":"4107_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-022-01684-5","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Molnupiravir: first approval. Drugs. 2022;82(4):455\u201360. https:\/\/doi.org\/10.1007\/s40265-022-01684-5.","journal-title":"Drugs."},{"key":"4107_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2022.121911","volume":"285","author":"AH Abdelazim","year":"2023","unstructured":"Abdelazim AH, Abourehab MA, Abd Elhalim LM, Almrasy AA, Ramzy S. Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form. Spectrochim Acta A: Mol Biomol Spectrosc. 2023;285:121911.","journal-title":"Spectrochim Acta A: Mol Biomol Spectrosc"},{"issue":"12","key":"4107_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14299","volume":"54","author":"JM Rivera-Caravaca","year":"2024","unstructured":"Rivera-Caravaca JM, Frost F, Mar\u00edn F, Lip GY. Impact of prior oral anticoagulation therapies on post-discharge outcomes after COVID-19: results from a global federated health network analysis. Eur J Clin Invest. 2024;54(12):e14299.","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"4107_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.803233","volume":"16","author":"PH Liu","year":"2022","unstructured":"Liu PH, Liu ZH, Niu MH, Chen P, Shi YB, He F, Guo R. A comparative study of the clinical benefits of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation with high bleeding risk. Front Cardiovasc Med. 2022;16(9):803233. https:\/\/doi.org\/10.3389\/fcvm.2022.803233.","journal-title":"Front Cardiovasc Med."},{"key":"4107_CR13","unstructured":"Rivaroxaban AET 10 mg, 15 mg and 20 mg film coated tablets. NL\/H\/3901\/001-003\/DC, Aug, 2018. https:\/\/db.cbg-meb.nl\/pars\/h120084.pdf."},{"key":"4107_CR14","unstructured":"Drug approval package. Xarelto (rivaroxaban) 10 mg immediate release Tablets, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022406Orig1s000TOC.cfm."},{"issue":"9","key":"4107_CR15","doi-asserted-by":"publisher","first-page":"2000243","DOI":"10.1002\/crat.202000243","volume":"56","author":"L Zhai","year":"2021","unstructured":"Zhai L, Zhang Z, Guo L, Zhu Z, Hu C, Zhang G. Synthesis, characterization, and properties of Rivaroxaban new crystalline forms. Cryst Res Technol. 2021;56(9):2000243.","journal-title":"Cryst Res Technol."},{"key":"4107_CR16","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.2147\/DDDT.S389884","volume":"16","author":"JH Kang","year":"2022","unstructured":"Kang JH, Lee JE, Jeong SJ, Park CW, Kim DW, Weon KY. Design and optimization of rivaroxaban-cyclodextrin-polymer triple complex formulation with improved solubility. Drug Des Devel Ther. 2022;16:4279\u201389.","journal-title":"Drug Des Devel Ther"},{"key":"4107_CR17","doi-asserted-by":"crossref","unstructured":"Abebe A, Akseli I, Sprockel O, Kottala N, Cuiti\u00f1o AM. Review of bilayer tablet technology. Int J Pharm. 2014;461","DOI":"10.1016\/j.ijpharm.2013.12.028"},{"key":"4107_CR18","doi-asserted-by":"crossref","unstructured":"Demiri V, Stranzinger S, Rinner P, Piller M, Sacher S, Lingitz J, et al. Gluing Pills Technology: A novel route to multilayer tablet manufacturing. Int J Pharm. 2018;548(1)","DOI":"10.1016\/j.ijpharm.2018.07.004"},{"key":"4107_CR19","doi-asserted-by":"crossref","unstructured":"Cai L, Farber L, Zhang D, Li F, Farabaugh J. A new methodology for high drug-loading wet granulation formulation development. Int J Pharm. 2013:441(1\u20132).","DOI":"10.1016\/j.ijpharm.2012.09.052"},{"key":"4107_CR20","unstructured":"USP-NF <616> Bulk Density of Powders. 2024 May."},{"key":"4107_CR21","unstructured":"USP-NF <1174> POWDER FLOW. 2024 May."},{"issue":"3","key":"4107_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","volume":"12","author":"S Klein","year":"2010","unstructured":"Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12(3):397\u2013406.","journal-title":"AAPS J."},{"key":"4107_CR23","unstructured":"Okponanabofa (Okpo) Eradiri. SBIA 2022: An in-depth look at the April 2022 Final FDA Guidance: Bioavailability studies submitted in NDAs or INDs \u2013 General Considerations October 26, 2022."},{"key":"4107_CR24","unstructured":"Stability Testing of New Drug Substances and Products Q1A(R2), Feb, 2003. Accessed 10\/02\/2026"},{"issue":"1","key":"4107_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1081\/DDC-120016686","volume":"29","author":"Y Huang","year":"2003","unstructured":"Huang Y, Khanvilkar KH, Moore AD, Hilliard-Lott M. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose. Drug Dev Ind Pharm. 2003;29(1):79\u201388.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"4107_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijpharm.2012.01.057","volume":"427","author":"JY Kim","year":"2012","unstructured":"Kim JY, Kim DW, Kuk YM, Park CW, Rhee YS, Oh TO, Weon KY, Park ES. Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes. Int J Pharm. 2012;427(2):201\u20138.","journal-title":"Int J Pharm"},{"issue":"7","key":"4107_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/pharmaceutics11070313","volume":"11","author":"KS Seo","year":"2019","unstructured":"Seo KS, Han HK. Multilayer-coated tablet of clopidogrel and rosuvastatin: Preparation and in vitro\/in vivo characterization. Pharmaceutics. 2019;11(7):313.","journal-title":"Pharmaceutics"},{"key":"4107_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121927","volume":"623","author":"DH Won","year":"2022","unstructured":"Won DH, Park H, Seo JW, Jang SW, Ha ES, Kim MS. Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl. Int J Pharm. 2022;623:121927.","journal-title":"Int J Pharm"},{"key":"4107_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.porgcoat.2020.105847","volume":"148","author":"SG Croll","year":"2020","unstructured":"Croll SG. Surface roughness profile and its effect on coating adhesion and corrosion protection: A review. Prog Org Coat. 2020;148:105847.","journal-title":"Prog Org Coat"},{"issue":"11","key":"4107_CR30","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1021\/acs.cgd.4c00376","volume":"24","author":"P Han","year":"2024","unstructured":"Han P, Wang L, Song S, Yao C, Tao X, Xie G, et al. Polymorphs and solvates of molnupiravir: crystal structures and solid forms transformation analysis. Crystal Growth Des. 2024;24(11):4758\u201369.","journal-title":"Crystal Growth Des"},{"key":"4107_CR31","volume":"4","author":"Y Meng","year":"2022","unstructured":"Meng Y, Tan F, Yao J, Cui Y, Feng Y, Li Z, Wang Y, Yang Y, Gong W, Yang M, Kong X. Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs. Int J Pharm : X. 2022;4:100119.","journal-title":"Int J Pharm : X"},{"issue":"6","key":"4107_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/ph18060761","volume":"18","author":"C Solomon","year":"2025","unstructured":"Solomon C, Anu\u021ba V, Sarbu I, Ozon EA, Musuc AM, Bratan V, et al. Enhancing the drug release and physicochemical properties of rivaroxaban via cyclodextrin complexation: a comprehensive analytical approach. Pharmaceuticals. 2025;18(6):761.","journal-title":"Pharmaceuticals"},{"key":"4107_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125661","volume":"677","author":"P Han","year":"2025","unstructured":"Han P, Wang L, Li H, Yao C, Qu Y, Zhang X, Zhao H, Ren Y, Li B, Xu L, Song W, Tao X. The new cocrystal of molnupiravir-caprolactam was discovered by melt crystallization with improved tableting properties. Int J Pharm. 2025;677:125661.","journal-title":"Int J Pharm"},{"key":"4107_CR34","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s10973-017-6412-3","volume":"130","author":"T Ding","year":"2017","unstructured":"Ding T, Chen L, Zhai L-H, Fu Y, Sun B-W. Compatibility study of rivaroxaban and its pharmaceutical excipients. J Therm Anal Calorim. 2017;130:1569\u201373. https:\/\/doi.org\/10.1007\/s10973-017-6412-3.","journal-title":"J Therm Anal Calorim."},{"issue":"9","key":"4107_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/pharmaceutics12090853","volume":"12","author":"KS Seo","year":"2020","unstructured":"Seo KS, Bajracharya R, Lee SH, Han HK. Pharmaceutical application of tablet film coating. Pharmaceutics. 2020;12(9):853.","journal-title":"Pharmaceutics"},{"key":"4107_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejps.2016.08.002","volume":"95","author":"A Komersov\u00e1","year":"2016","unstructured":"Komersov\u00e1 A, Locha\u0159 V, Mysl\u00edkov\u00e1 K, Mu\u017e\u00edkov\u00e1 J, Barto\u0161 M. Formulation and dissolution kinetics study of hydrophilic matrix tablets with tramadol hydrochloride and different co-processed dry binders. Eur J Pharm Sci. 2016;95:36\u201345.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4107_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejpb.2014.02.008","volume":"87","author":"N Jedinger","year":"2014","unstructured":"Jedinger N, Khinast J, Roblegg E. The design of controlled-release formulations resistant to alcohol induced dose dumping\u2013a review. Eur J Pharm Biopharm. 2014;87(2):217\u201326.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4107_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1208\/s12248-015-9830-9","volume":"18","author":"DA Diaz","year":"2016","unstructured":"Diaz DA, Colgan ST, Langer CS, Bandi NT, Likar MD, Van Alstine L. Dissolution similarity requirements: how similar or dissimilar are the global regulatory expectations? AAPS J. 2016;18(1):15\u201322.","journal-title":"AAPS J"},{"key":"4107_CR39","unstructured":"Xarelto, INN-Rivaroxaban. Available from: http:\/\/www.emea.europa.eu. Accessed on 12\/10\/2025."},{"issue":"6","key":"4107_CR40","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1208\/s12249-014-0164-1","volume":"15","author":"VV Kulthe","year":"2014","unstructured":"Kulthe VV, Chaudhari PD. Effectiveness of spray congealing to obtain physically stabilized amorphous dispersions of a poorly soluble thermo sensitive API. AAPS Pharm SciTech. 2014;15(6):1370\u20137.","journal-title":"AAPS Pharm SciTech"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04107-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04107-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04107-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:47:20Z","timestamp":1790005640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04107-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04107-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interest to declare.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}